DOACs, CAD, and PCI: How to Treat?cme



FACULTY



Deepak L. Bhatt, MD, MPH
Professor of Medicine
Harvard Medical School
Executive Director
Interventional Cardiovascular
Programs
Brigham and Women's Hospital
Heart & Vascular Center
Boston, Massachusetts



Roxana Mehran, MD
Professor of Medicine
Director of Interventional
Cardiovascular Research
and Clinical Trials
Icahn School of Medicine
at Mount Sinai
New York, New York

Supported by an independent educational grant from Janssen Pharmaceuticals. Inc.

Developed through a collaboration between the University of Chicago Medicine and Medscape Education.





DOACs, CAD, and PCI: How to Treat? CME

TARGET AUDIENCE

This activity is intended for cardiologists, primary care physicians, and surgeons.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Clinical data supporting the use of factor Xa inhibitor therapy for treatment of patients with coronary artery disease (CAD) who are undergoing percutaneous coronary intervention (PCI)
- Latest recommendations on the use of antithrombotic therapy in patients with CAD who are undergoing PCI

ACCREDITATION STATEMENT

For Physicians



The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of 0.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To access this free CME activity, please visit